High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer
Phase 2 Unknown
30 enrolled
T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy
Phase 2 Unknown
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
Phase 2/3 Unknown
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Unknown
Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Phase 3 Unknown
630 enrolled
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Phase 3 Unknown
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Phase 3 Unknown
Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Unknown
ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer
Phase 2 Unknown
SU006668 in Treating Patients With Advanced Solid Tumors
Phase 1 Unknown
Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 2 Unknown
Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
Phase 3 Unknown
1,800 enrolled
Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Phase 3 Unknown
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Phase 2 Unknown
Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
Phase 3 Unknown
200 enrolled
Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Phase 3 Unknown
300 enrolled
Mistletoe in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Are Receiving Palliative Chemotherapy
Phase 2 Unknown
Quality of Life in Patients Who Are Receiving Either Vinorelbine, Gemcitabine, and Docetaxel or Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer
Unknown
Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Phase 2 Unknown
38 enrolled
Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer
Phase 2 Unknown
20 enrolled
Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer
Phase 1/2 Unknown
Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer
Phase 2 Unknown
Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer
Phase 2 Unknown
30 enrolled
Diagnosis and Treatment Planning in Patients Suspected of Having Lung Cancer
Phase NA Unknown
INS316 Compared With Saline for Sputum Collection in Diagnosing Lung Cancer
Phase NA Unknown
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase 2 Unknown
Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
Unknown
408 enrolled
Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed
Phase 3 Unknown
750 enrolled
Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer
Phase 1 Unknown
30 enrolled
Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer
Phase 3 Unknown
250 enrolled
Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
Phase 1 Unknown
Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer
Phase 3 Unknown
430 enrolled
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
18 enrolled
Screening to Predict Weight Loss in Patients With Cancer
Phase NA Unknown
220 enrolled
Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 3 Unknown
1,350 enrolled
Biomarkers for Early Detection of Lung Cancer in Patients With Lung Cancer, Participants at High-Risk for Developing Lung Cancer, or Healthy Volunteers
Unknown
300 enrolled
Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
Phase NA Unknown
500 enrolled
Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
Phase 2 Unknown
170 enrolled
Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 2 Unknown
150 enrolled
Studying Patterns, Causes, and Control of Disease in Patients With Lung Cancer in the North Trent (England) Region
Unknown
2,000 enrolled
Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Unknown
26 enrolled
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Phase 3 Unknown
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
Phase 3 Unknown
242 enrolled
Liverpool Lung Project: Risk Factors and Genetic Markers in Healthy Participants and Patients With Lung Cancer
Unknown
8,300 enrolled
Dalteparin in Preventing Blood Clots in Patients With Lung Cancer
Phase 3 Unknown
2,200 enrolled
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Phase 2 Unknown
250 enrolled
First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase 2 Unknown
117 enrolled
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
Phase 2 Unknown
47 enrolled
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase 1 Unknown
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Phase 1 Unknown